

Press release from Emotra AB (publ)
Göteborg, January 17, 2014

Emotra signs co-operation agreement with psychiatric clinic in Genoa

Emotra has signed a co-operation agreement with a psychiatric clinic at the University of Genoa. This is the fourth clinic to sign an agreement to participate in Emotra's clinical multi-centre study for the purpose of evaluating the use of EDOR to assess potential suicide risks.

"The psychiatric clinic at the University of Genoa is the first Italian clinic to sign an agreement regarding co-operation in our multi-centre study. We are engaged in far-reaching discussions with a number of other clinics in Italy, so I don't think Genoa will be the only Italian clinic to participate in this study," states Claes Holmberg, CEO of Emotra AB.

So far, four clinics have signed co-operation agreements with Emotra. Emotra plans to involve 15 leading European clinics in the evaluation of the method over the next two years, and discussions and negotiations are ongoing with several clinics from different countries. For the purpose of preparing these clinical studies, applications to ethical committees as well as for CE certification are simultaneously being drafted.

At present, Emotra is in the middle of a very dynamic phase, and its activities involve an increasing number of clinical centres. In order to minimise the financial risks, all work is carried out within a small organisation and as cost-effectively as possible. When international, scientific support for EDOR from these clinics has grown sufficiently strong, we will launch the method in Europe.

For further information, please contact:

Claes Holmberg, CEO

Telephone: +46 708 25 45 47

E-mail: claes@emotra.se

Lars-Håkan Thorell, Head of Research

Telephone: +46 733 95 31 20

E-mail: lars@emotra.se

Emotra AB is listed on AktieTorget, and the Company has developed a method – EDOR – of detecting depressed patients who are at risk of committing suicide. Altogether, more than 1,000 patients have been tested and followed up. EDOR has shown a reliability rate of up to 97%. In other words, Emotra's method can determine, with 97% certainty, if a person runs a significantly higher risk of suicide attempt, facilitating decisions about where special suicide prevention measures are needed. EDOR helps the right patients get the care they need.